Argent Biopharma Limited has released a press release.
Completion of CimetrA Mechanism of Action study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Provision of US$600,000 Funding and change of CFO
- Refinancing and Extension to Convertible Security Agreements
- Results of CimetrA bioanalytics pre-clinal trial
- Internal Costs Review Completed and Board Change
- $800,000 of funding received through Mercer Facility
Later from Argent Biopharma
- ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order
- MGC Receive Permission for Psilocybin Research & Development
- Funding Commitments Received for GBP 1.8m
- CannEpil now available by Named Patient Request in UK
- Fundraise closed raising up to a total of GBP 2.09m
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma